Stock Chart

JBIO

$15.87 -4.05%
Score: 30.2 AVOID NEW MONEY
Pro
Screener
Vol: 1.05x (vs SPY: 1.4x | vs QQQ: 1.5x)
Volume Ratio Explained

Vol: Current volume vs 20-day average
vs SPY: Relative activity vs market
vs QQQ: Relative activity vs tech

Color Guide:
● Red (≥1.5x): High activity
● Yellow (≥1.2x): Above average
● Blue (≤0.7x): Low activity

Interpretation:
• vs SPY > 1: Stock-specific interest
• vs SPY < 1: Stock quiet vs market
Chart Pattern · as of Nov 12, 2026
No qualifying chart pattern in the trailing 60 sessions — we only flag setups that pass our quality gate.
Technical Chart
CHART OVERLAYS
Active: 2
INDICATORS
TRENDLINES
OPTIONS FLOW
VOLUME & PRICE
OTHER

About JBIO - Jade Biosciences, Inc. Common Stock

Jade Biosciences Inc is focused on developing therapies to address critical unmet needs in autoimmune diseases. Its asset, JADE-001, will target the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for immunoglobulin A (IgA) nephropathy, with Investigational New Drug Application-enabling studies underway and initiation of a first-in-human trial. Jade's pipeline also includes two undisclosed optimized antibody discovery programs, JADE-002 and JADE-003, currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount.

Key Statistics

Market Cap $1B

This JBIO stock chart provides comprehensive technical analysis including candlestick patterns, volume profile analysis, and options open interest data. Track JBIO's price movements with trendlines, gamma walls, and key support/resistance levels.